Domestic demand lifts Torrent and Mankind in June quarter
India-focused growth powered June-quarter results: Torrent Pharma’s domestic business rose 19% while Mankind Pharma’s India formulations grew 11%, outperforming pressure in US generics markets.
Torrent Pharma and Mankind posted strong June-quarter earnings, supported by double-digit growth in India-focused businesses. Torrent’s domestic sales rose a record 19%, while Mankind’s India formulations grew 11%, underscoring resilient local demand versus pressured US generics markets.
Why this matters
Torrent Pharmaceuticals' domestic strength follows Q1 reports of 55% revenue growth after the JB Pharma acquisition and a 3.3% PAT rise, highlighting India demand as a growth contributor amid US generics pressure.
Retail-company signals are accelerating, up 253820% QoQ.